Maven Securities LTD Invests $866,000 in SOPHiA GENETICS SA $SOPH

Maven Securities LTD acquired a new stake in shares of SOPHiA GENETICS SA (NASDAQ:SOPH) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 150,000 shares of the company’s stock, valued at approximately $866,000. Maven Securities LTD owned about 0.18% of SOPHiA GENETICS at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of SOPH. Perkins Capital Management Inc. acquired a new position in SOPHiA GENETICS in the 4th quarter worth about $49,000. Squarepoint Ops LLC acquired a new stake in shares of SOPHiA GENETICS during the 3rd quarter valued at about $49,000. First Dallas Securities Inc. bought a new stake in shares of SOPHiA GENETICS in the 1st quarter valued at approximately $50,000. Quadrature Capital Ltd acquired a new position in SOPHiA GENETICS in the fourth quarter worth approximately $54,000. Finally, XTX Topco Ltd acquired a new position in SOPHiA GENETICS in the fourth quarter worth approximately $55,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on SOPH. HC Wainwright raised their price objective on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. BTIG Research boosted their target price on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Finally, Zacks Research upgraded shares of SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, SOPHiA GENETICS presently has a consensus rating of “Hold” and an average price target of $10.00.

Insider Transactions at SOPHiA GENETICS

In other news, Director Kathy L. Hibbs sold 6,250 shares of the stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $8.68, for a total value of $54,250.00. Following the completion of the sale, the director directly owned 103,242 shares of the company’s stock, valued at approximately $896,140.56. This represents a 5.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CTO Abhimanyu Verma sold 5,000 shares of the stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $8.80, for a total value of $44,000.00. Following the completion of the sale, the chief technology officer directly owned 172,171 shares of the company’s stock, valued at $1,515,104.80. This represents a 2.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 336,342 shares of company stock worth $2,154,775. Insiders own 4.88% of the company’s stock.

SOPHiA GENETICS Stock Up 3.3%

SOPH stock opened at $8.36 on Wednesday. The stock has a market capitalization of $701.36 million, a price-to-earnings ratio of -7.27 and a beta of 0.98. The company has a 50-day moving average of $6.89 and a two-hundred day moving average of $5.63. SOPHiA GENETICS SA has a 52-week low of $3.10 and a 52-week high of $8.98. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 2.55.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%.The business had revenue of $23.31 million during the quarter, compared to the consensus estimate of $21.72 million. As a group, equities research analysts anticipate that SOPHiA GENETICS SA will post -0.77 EPS for the current year.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.